The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Sapir Alex since 2017.
This trader's CIK number is 1709415.
At the time of last reporting, Sapir Alex was the See Remarks of Fulcrum Therapeutics, Inc.. (stock ticker symbol FULC).
Also see all insider trading activities at Fulcrum Therapeutics, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2023 | PHAS | 0 | $0 | 0 | $0 | 3,750 | $0 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2024 | FULC | 0 | $0 | 0 | $0 | 150,000 | $490,500 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2018 | DOVA | 21,700 | $495,410 | 0 | $0 | 0 | $0 |
| 2017 | DOVA | 20,100 | $341,700 | 0 | $0 | 26,809 | $99,997 |
1. Phasebio Pharmaceuticals Inc (PHAS)
2. Fulcrum Therapeutics, Inc. (FULC)
3. Dova Pharmaceuticals Inc. (DOVA)
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2023-05-19 | PHAS | Option Ex | 3,750 | .00 | 0 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2024-07-03 | FULC | Option Ex | 150,000 | 3.27 | 490,500 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2018-08-14 | DOVA | Buy | 21,700 | 22.83 | 495,410 |
| 2017-12-22 | DOVA | Option Ex | 26,809 | 3.73 | 99,997 |
| 2017-07-05 | DOVA | Buy | 20,100 | 17.00 | 341,700 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Sapir Alex (See Remarks of Fulcrum Therapeutics, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.